2008
DOI: 10.1254/jphs.fp0072181
|View full text |Cite
|
Sign up to set email alerts
|

Systemic Glucocorticoid Therapy Reduces Pain and the Number of Endoneurial Tumor Necrosis Factor-Alpha (TNFα)-Positive Mast Cells in Rats With a Painful Peripheral Neuropathy

Abstract: Abstract. Clinical and experimental evidence suggests that glucocorticoids may be effective in the treatment of neuropathic pain, but their mechanism of action is unknown. We gave triamcinolone (3 mg / kg) to rats with an experimental post-traumatic painful peripheral neuropathy, chronic constriction injury (CCI), five days after nerve injury, when the abnormal pain syndrome is known to be present; and pain sensitivity was measured on postoperative days 7 -14, a period during which symptoms are known to be at … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
29
0
1

Year Published

2010
2010
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(31 citation statements)
references
References 37 publications
1
29
0
1
Order By: Relevance
“…Pharmacological treatments that failed to decrease these levels included monotherapy of paracetamol, tramadol, cannabidiol, morphine, soluble TNF receptor, and IL-1 receptor antagonist. On the other hand, successful interventions that lower TNF- α expression included NMDA receptor antagonist MK-801, thalidomide, combined therapy of soluble TNF receptor with IL-1 receptor antagonist, chronic administration of morphine (dose-dependant with aggravation after interruption), α2-macroglobulin, nimesulide, a combination of paracetamol with tramadol, recombinant human erythropoietin and triamcinolone [32, 3436, 43, 45, 55, 61, 62, 64]. …”
Section: Resultsmentioning
confidence: 99%
“…Pharmacological treatments that failed to decrease these levels included monotherapy of paracetamol, tramadol, cannabidiol, morphine, soluble TNF receptor, and IL-1 receptor antagonist. On the other hand, successful interventions that lower TNF- α expression included NMDA receptor antagonist MK-801, thalidomide, combined therapy of soluble TNF receptor with IL-1 receptor antagonist, chronic administration of morphine (dose-dependant with aggravation after interruption), α2-macroglobulin, nimesulide, a combination of paracetamol with tramadol, recombinant human erythropoietin and triamcinolone [32, 3436, 43, 45, 55, 61, 62, 64]. …”
Section: Resultsmentioning
confidence: 99%
“…Glucocorticoids, which broadly and nonspecifically suppress the immune response, are commonly used in clinical practice to alleviate neuropathic pain in conditions such as lumbar radiculopathy and to prevent inflammation following nerve damage, such as spinal cord injury [104,105]. They have also been found to prevent development of neuropathic pain [106], possibly through a decrease in TNF-α concentrations in mast cells [107]. However, despite a number of clinical trials for various conditions, the true clinical effectiveness of glucocorticoids for neuropathic pain remains unclear [108].…”
Section: Alternative Approaches To Reduce Neuroinflammmationmentioning
confidence: 99%
“…31 We cannot yet state that the mechanisms of proinflammatory cytokines associated with the regulation of thoracotomy and rib retraction induced neuropathic pain, but increased TNF-α was shown in Schwann cells and mast cells of the injured sciatic nerve in rats after peripheral nerve injury. 45 Furthermore, activation of local Schwann cells is followed by increased production of TNF-α and IL-1β. 46 In this direction, it is believed that anti-inflammatory cytokines and proinflammatory cytokine inhibitors reduce neuropathic pain.…”
Section: Time Frame Of Mechanical Testingmentioning
confidence: 99%